Literature DB >> 28284317

The level of diagnostic assessment in severe asthma: A nationwide real-life study.

Anna von Bülow1, Vibeke Backer2, Uffe Bodtger3, Niels Ulrik Søes-Petersen4, Karin Dahl Assing5, Tina Skjold6, Celeste Porsbjerg2.   

Abstract

INTRODUCTION: Systematic assessment of patients with severe asthma is pivotal to decide which patients are eligible to new biological therapies. However, the level of diagnostic work-up in patients with severe asthma is only poorly investigated. AIMS &
OBJECTIVES: To describe the diagnostic work-up in a complete population of patients with severe asthma including: objective confirmation of the asthma diagnosis, and identification of potential treatment barriers, such as poor adherence and poor inhaler technique.
METHODS: A retrospective cross-sectional multicenter study was performed in 2013. We evaluated patient record forms of all patients (aged 18-65 years) consecutively referred with asthma to one of five respiratory outpatient clinics over two years. Patients were included in the study, if they fulfilled ERS/ATS guidelines for having severe asthma.
RESULTS: Among 1563 patients with asthma, 98 (6.3%) patients fulfilled the criteria for having severe asthma. The diagnosis of asthma was confirmed objectively in 53/98 patients (54.1%). In total, 83.7% underwent at least one diagnostic test for asthma: reversibility test: 63.3%, PEF: 52% and bronchial challenge test: 21.4%. Among patients eligible for a bronchial challenge test (FEV1 ≥ 70%; negative PEF measurement/reversibility test), only 23.1% had such a test performed. Inhalation technique and adherence were assessed in 19.4 and 30.6% of patients, respectively.
CONCLUSION: Among patients managed for severe asthma in a specialist setting, only half had the asthma diagnosis confirmed objectively, and adherence and inhaler technique were infrequently assessed.
Copyright © 2017 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Asthma; Asthma assessment; Asthma diagnosis; Asthma management; Difficult to treat asthma; Severe asthma

Mesh:

Year:  2017        PMID: 28284317     DOI: 10.1016/j.rmed.2017.01.010

Source DB:  PubMed          Journal:  Respir Med        ISSN: 0954-6111            Impact factor:   3.415


  5 in total

1.  Using a knowledge translation framework to identify health care professionals' perceived barriers and enablers for personalised severe asthma care.

Authors:  Eleanor C Majellano; Vanessa L Clark; Rebecca F McLoughlin; Peter G Gibson; Vanessa M McDonald
Journal:  PLoS One       Date:  2022-06-07       Impact factor: 3.752

Review 2.  Nordic consensus statement on the systematic assessment and management of possible severe asthma in adults.

Authors:  Celeste Porsbjerg; Charlotte Ulrik; Tina Skjold; Vibeke Backer; Birger Laerum; Sverre Lehman; Crister Janson; Thomas Sandstrøm; Leif Bjermer; Barbro Dahlen; Bo Lundbäck; Dora Ludviksdottir; Unnur Björnsdóttir; Alan Altraja; Lauri Lehtimäki; Paula Kauppi; Jussi Karjalainen; Hannu Kankaanranta
Journal:  Eur Clin Respir J       Date:  2018-03-06

Review 3.  Efficacy, adverse events, and inter-drug comparison of mepolizumab and reslizumab anti-IL-5 treatments of severe asthma - a systematic review and meta-analysis.

Authors:  Daniel P Henriksen; Uffe Bodtger; Kirsten Sidenius; Niels Maltbaek; Lars Pedersen; Hanne Madsen; Ehm A Andersson; Ole Norgaard; Louise Klokker Madsen; Bo L Chawes
Journal:  Eur Clin Respir J       Date:  2018-11-07

Review 4.  Difficult and Severe Asthma in Children.

Authors:  Federica Porcaro; Nicola Ullmann; Annalisa Allegorico; Antonio Di Marco; Renato Cutrera
Journal:  Children (Basel)       Date:  2020-12-10

5.  The Danish severe asthma register: an electronic platform for severe asthma management and research.

Authors:  Susanne Hansen; Ole Hilberg; Charlotte Suppli Ulrik; Uffe Bodtger; Linda M Rasmussen; Karin D Assing; Alexandra Wimmer-Aune; Kirsten B Rasmussen; Niels Bjerring; Anders Christiansen; Johannes Schmid; Niels Steen Krogh; Celeste Porsbjerg
Journal:  Eur Clin Respir J       Date:  2020-11-02
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.